(ADCs) and renewing interest in targeted radioimmunoconjugates highlighted by commercial momentum and patent consolidation from Roche/Genentech, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Pfizer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results